Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States

Hepatitis C. 2015. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/ . [Accessed 8/27/2015].

Centers for Disease Control and Prevention. Notes from the field: risk factors for hepatitis C virus infections among young adults—Massachusetts, 2010. In: MMWR. 2011. p. 1457–8.

Centers for Disease Control and Prevention. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men New York City, 2005–2010. In: MMWR. 2011. p. 945–50.

Simmons B et al. Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. Clin Infect Dis. 2015;61(5):730–40.

Afdhal N et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–93.

Afdhal N et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–98.

Cousien A et al. Hepatitis c treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology. 2015;63(4):1090-101.

Trooskin SB, Reynolds H, Kostman JR. Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy. Clin Infect Dis. 2015;61(12):1825-30.

Van Nuys K et al. Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern. Health Aff (Millwood). 2015;34(10):1666–74.

Overview of Cost, Reimbursement, and Cost-Effectiveness Considerations for Hepatitis C Treatment Regimens. Available from: http://www.hcvguidelines.org/full-report/overview-cost-reimbursement-and-cost-effectiveness-considerations-hepatitis-c-treatment . [Accessed 10/20/15].

The Health Strategies Consultancy Prepared for the Kaiser Family Foundation. Follow The Pill: Understanding the U.S. Commercial Pharmaceutical Supply Chain. 2005. p. 32.

Congressional Budget Office. Prescription Drug Pricing in the Private Sector. 2007. p. 26.

Silverman E. U.S. Could Save up to $16B if Medicare Part D Prices are Negotiated: Paper. NYC, NY: The Wall Street Journal Blog; 2015.

Center for Medicare Advocacy. Part D/Prescription Drug Benefits. Available from: http://www.medicareadvocacy.org/medicare-info/medicare-part-d/ - covered%20drugs. [Accessed 10/28/15].

Pollack A. Sales of Sovaldi, New Gilead Hepatitis C Drug, Soar to $10.3 Billion. NYC, NY: The New York Times; 2015.

Silverman, E. What the ‘Shocking’ Gilead Discounts on its Hepatitis C Drugs Will Mean. NYC, NY: The Wall Street Journal; 2015.

Graham CS, Swan T. A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Res. 2015;119:89–96.

Kamal-Yanni M. Hepatitis C drug affordability. Lancet Glob Health. 2015;3(2):e73–4.

World Health Organization. Cost-Containment Mechanisms for Essential Medicines, Including Antiretrovirals, in China - Health Economics and Drugs Series No. 013, Essential Medicines and Health Products Information Portal - A World Health Organization resource. 2003.

Gilead Sciences. CHRONIC HEPATITIS C TREATMENT EXPANSION Generic Manufacturing for Developing Countries. 2015.

Bristol-Myers Squibb. HCV Developing World Strategy. 2015.

Doctors Without Borders. Gilead Denied Patent for Hepatitis C Drug Sofosbuvir in India. 2015.

Borders DW. China Rejects Gilead Patent on Hepatitis C Drug Sofosbuvir 6/19/2015. Available from http://www.doctorswithoutborders.org/article/china-rejects-gilead-patent-hepatitis-c-drug-sofosbuvir . Accessed 3/6/2016.

Chhatwal J, He T, Lopez-Olivo MA. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. Pharmacoeconomics. 2016. [epub ahead of print].

Najafzadeh M et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015;162(6):407–19.

Leidner AJ et al. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology. 2015;61(6):1860–9.

Linas BP et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med. 2015;162(9):619–29.

Everson GT et al. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015;163(11):818–26.

Feld JJ et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015;373(27):2599–607.

Foster GR et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015;373(27):2608–17.

Barua S et al. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. Ann Intern Med. 2015;163(3):215–23.

AASLD/IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. 2015.

Silverman E. Gilead Limits Enrollment in its Hep C Patient Programs to Pressure Insurers. NYC, NY: The Wall Street Journal Blog; 2015.